
    
      The study consists of:

        -  a screening phase (maximum length of 7-day).

        -  a treatment phase with 21-day study treatment cycles. Patients continue to receive
           treatment until disease progression , death, unacceptable toxicity, investigator's
           decision or withdrawal of consent.

        -  a 30-day follow-up visit after the last dose of study medication.
    
  